Summary Twelve patients with small cell lung cancer were treated with recombinant human granulocyte colony-stimulating factor, rhG-CSF, given by continuous infusion at doses ranging from 1 to 40 ig kg-'day-'. Patients received the rhG-CSF before the start of intensive chemotherapy and after alternate cycles of chemotherapy. Several in vitro assays were performed using peripheral blood neutrophils and marrow progenitor cells collected from patients prior to and after infusion of the growth factor. Peripheral blood neutrophils were tested for mobility and phagocytic activity. In addition, in vitro clonogenic assays of marrow haemopoietic progenitor cells and analysis of bone marrow trephines and aspirates were carried out. We found that rhG-CSF in vivo has at least two main effects: (a) an early fall in peripheral neutrophils, within the first hour, followed by a rapid influx of mature neutrophils into the circulatory pool; (b) stimulation of proliferation and differentiation of neutrophil precursors in the bone marrow. Neutrophils released into the circulation were normal in tests of their mobility and phagocytic activity.
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In recent years a variety of growth factors have been described which stimulate the proliferation and differentiation of multipotent and lineage-restricted haemopoietic progenitor cells in vitro (Metcalf, 1986; Sieff, 1987) and promote the functional activation of mature cells (Fleischmann et al., 1986; Nicola, 1987) .
The genes for many of these growth factors have been molecularly cloned and their products expressed in bacteria. The large amount of material thus generated has allowed an analysis of the effects of these growth factors when administered in vivo. Stimulation of granulopoiesis in vivo by recombinant human granulocyte colony-stimulating factor (rhG-CSF, Souza et al., 1986) has been documented in mice by Moore & Warren (1987) , who also showed a synergy of this growth factor with interleukin-1, and in monkeys by Welte et al. (1987) . Granulocyte-macrophage colonystimulating factor has been shown to stimulate haemopoiesis in vivo both in animals (Donahue et al., 1986) and in patients (Groopman et al., 1987; Vadhan-Raj, et al., 1987) .
We have demonstrated the value of a colony-stimulating factor, rhG-CSF, in reducing the period of neutropenia (by a median of 80%) in patients treated with intensive chemotherapy, with a parallel protective effect against severe infections (Bronchud et al., 1987) . In this study, twelve patients with small cell lung cancer received recombinant human granulocyte colony-stimulating factor (rhG-CSF) given by continuous infusion before the start -and after alternate cycles of intensive chemotherapy.
Here we present the time course of response to rhG-CSF in these patients as well as neutrophil function tests, bone marrow clonogenic assays and histology before and after the infusion of growth factor.
Materials and methods

Patients
Twelve patients with advanced small cell lung cancer gave their informed consent to enter the study, under the guidelines of the district medical ethics committee. The study design has been described in our previous paper (Bronchud et al., 1987 Polymorph phagocytic function Phagocyte function was measured essentially as described by Easmon et al. (1980) Ltd., 1988 Br. J. Cancer (1988 1251 Luminometer and the results expressed as mean values for the peak chemiluminescence (in mV). All samples were set up in duplicate and a control blood sample was tested simultaneously with each patient sample.
Polymorph chemotaxis Polymorph mobility was measured by the technique of migration under agarose essentially as described by Nelson et al. (1975) . Briefly, agarose plates (0.75% agarose in RPMI-H supplemented with 10% pooled human plasma and 2mM glutamine) were punched to give 6 groups of 3 wells (3mm wells with 3mm between wells). The centre well in each group of 3 was filled with 10 MI cell suspension (adjusted to give 5 x 105 polymorphs/well). One of the remaining wells was filled with 101 RPMI-H and the other with 10,ul chemotactic agent (N-formyl-methionylleucyl-phenylalanine, Sigma) at 6 concentrations (10-6 M and serial 2-fold dilutions). Migration distances towards the control (medium) well and the chemotactic agent were measured after 2 h at 37 C (in 5% CO2) under the microscope using a calibrated eycpiece, and values were expressed in mm x 102 as a specific migration distance by subtracting the control distance from the chemotactic distance. In each test a normal control blood sample was tested simultaneously with the patient's sample.
In vitro survival of peripheral neutrophils Different concentrations of leucocytes from rhG-CSF treated patients and a normal control, purified by density-gradient centrifugation of a leucocyte cell suspension over Lymphoprep separation medium (Nycomed) to deplete mononuclear cells, were plated with and without rhG-CSF (3 x 10i U ml-1) and live cell numbers were counted on a haemocytometer after staining with Trypan blue over a period of 6 days.
Neutrophil alkaline phosphatase The activity of this enzyme was determined daily during the phase I part of the study as described by Rutenberg (1965) . A normal blood film and a blood film giving a strong reaction were used as controls.
Clonal assays for haemopoietic cells All methods were essentially as described before (Metcalf, 1977; Testa, 1985) with minor modifications.
Cells Bone marrow cells were obtained by aspiration from the posterior superior iliac crest before and after 5 days of continuous infusion of rhG-CSF (via central line) during the phase I part of our study. Cells were collected in Iscove's medium (Gibco) with 40ml-1 of preservative free heparin (sodium heparin Weddel Pharmaceuticals Ltd.) and red blood cells were separated by sedimentation in 0.1% methylcellulose over 30min at room temperature. Bone marrow aspirates were obtained at the same time as bone marrow trephines and smears were stained conventionally with May-Grumwald-Giemsa. The myeloid-erythroid ratios and differential counts were determined for each patient, and results analysed by the Wilcoxon matched-pairs signed-ranks test.
Results
All 12 patients in our study responded to rhG-CSF with a specific increase in peripheral neutrophils (6 to 10-fold) up to a maximum of 100 x 1091-1 at lOjpg kg-l day-1 of rhG-CSF. There were no appreciable changes in monocytes, eosinophils, platelets, lymphocytes or haemoglobin (Bronchud, et al., 1987) .
As shown in Figure 1 , following infusion of rhG-CSF, there was a rapid but selective and transient fall in the number of peripheral neutrophils, followed by an increase 2 to 8 h later. We have shown previously (Bronchud et al., 1987) that the increase in peripheral neurophils was maintained for as long as the infusion of rhG-CSF continued, but the counts fell back to normal levels within 24 to 48 h after stopping the growth factor infusion. Table II shows that peripheral neutrophils after 3 days of rhG-CSF infusion were normal in tests of their mobility and phagocytic functions. The latter (as reflected by the chemiluminescence values) was usually increased (up to 2-fold) by rhG-CSF treatment and when it reached high values, neutrophil mobility appeared slightly reduced. Similar results were also obtained with peripheral neutrophils from rhG-CSF patients were treated with rhG-CSF, and this was a bronchopneumonia in a non-neutropenic patient who had not e-response curves to responded to chemotherapy (Bronchud, et al., 1987; and and 9 (0). Patients Table I ). taken at zero time,
We decided to investigate whether rhG-CSF can confer an sion of growth factor increased survival to peripheral neutrophils (Figure 2 fact, most patients receiving 10-40 pgkg-'day-' rhG-CSF had a median of 4% of peripheral metamyelocytes (range 1-15%) after -48h and 2% myelocytes (range 1-4%) after 4 days of growth factor infusion. More importantly, however, no blast cells were ever seen. This contamination of peripheral blood leucocytes by immature forms might also help to explain the reduction in neutrophil mobility found in patients 3 and 6 on recovery from the nadir induced by chemotherapy, since both patients had significant numbers of immature forms at the time of sampling (10% and 14% respectively).
The neutrophil alkaline phosphatase activity also increased in all patients after -48 h of rhG-CSF infusion, up to a maximum of 389 at 10 pg kg-day-1 (normal range is 15-100).
Another measure of dynamic changes in response to rhG-CSF was shown by the hypercellularity seen in bone marrow trephines of all patients following growth factor treatment during the phase I part of the study (Figure 3) . Coded samples taken before and after the infusion of growth factor could be easily distinguished, and the median absolute increase in cellularity was 20% (from 30% pre-therapy to 50% post). A bone marrow trephine was also obtained from patient 4 when rhG-CSF was given after the sixth and last cycle of chemotherapy and showed a comparable degree of hypercellularity at the time of recovery from the chemotherapy induced neutrophil nadir. The proportion of cycling haemopoietic progenitor cells (Table III) was only slightly increased by rhG-CSF treatment (median of 8.5%, P=0.028).
The GM-CFC/BFU-E ratio was not statistically different (P = 0.25) after 5 days of rhG-CSF infusion (Table III) . However, the myeloid-erythroid ratio in bone marrow aspirates was significantly raised (P=0.028), up to 5-fold pretreatment values, by the growth factor infusion (Table IV) .
We found no evidence of a stimulatory effect of rhG-CSF on small cell lung cancer. Thus a repeat bone marrow (Table I) compares favourably with the best published series for advanced small cell lung cancer (Spiro, 1985) . The median survival of the 8 evaluable patients with histologically proven advanced small cell lung cancer is now 8 months and 4 patients remain alive and on follow up (Table I) . Small cell carcinoma cells were grown in vitro from the bone marrow of another patient, but did not respond to the presence of rhG-CSF in the medium and they died within 10 days.
One patient died during the study while receiving rhG-CSF (8R) and microscopic evidence of some extramedullary haemopoiesis in the spleen was found at post-mortem.
Discussion
Our results suggest that rhG-CSF in vivo has at least two main effects: (a) an early fall in peripheral neutrophils within the first hour, followed by a rapid influx of mature neutrophils into the circulatory pool; (b) stimulation of proliferation and differentiation of neutrophil precursors in the bone marrow.
The early influx occurs between 2 and 8 hours after the start of the continuous infusion of rhG-CSF (Figure 1 ) and is specific for neutrophils. Initially, only mature neutrophils are released into the circulation, but at high doses of rhG-CSF some metamyelocytes and myelocytes are also seen in the peripheral blood after 2 or 3 days. This response is quite different from the biphasic leucocyte changes which are seen following the parenteral administration of epinephrine (Samuels, 1951) which causes a prompt mobilisation of all white cell elements (maximal within 20 minutes) thought to be secondary to demargination of leucocytes from postcapillary venules. In fact, during the first hour of the rhG-CSF infusion we found a transient decrease in peripheral neutrophils with no significant change in other circulating cell numbers. The reason for this initial decrease is unclear and requires further investigation, but it might be related to migration of circulating neutrophils into tissues or to increased adherence of neutrophils to endothelium. Similar findings have been recently reported by Morstyn et al. (1988) following rhG-CSF given by short intravenous infusion. The subsequent rise in peripheral neutrophils produced by rhG-CSF is probably due to an increase in the influx of cells from the bone marrow (both mature and de novo granulocytes). This is similar to one of the mechanisms proposed for cortisone-induced neutrophil leucocytosis, but the latter is also known to result from a decreased efflux of cells from the blood (Bishop et al., 1968) , and it is not associated with a net increase in the rate of bone marrow neutrophil production (Vincent, 1977) .
It is possible that part of the explanation for the increased neutrophil count is due to prolonged survival of myeloid cells in the presence of rhG-CSF. Our analysis in vitro suggests that the growth factor does not significantly prolong survival of either control cells or cells obtained from patients treated with growth factor. However, a marginal increase in neutrophil survival in vitro, between 24 and 40 hours, has been reported by Begley et al. (1986) when neutrophils were plated at much lower densities in the presence of purified murine G-CSF. We did not look for such effect. The finding that peripheral neutrophil counts in patients return to normal levels within 24-48 hours after stopping the growth factor infusion also agrees with the best estimates of the normal half-life of circulating neutrophils in vivo (about 8 hours, Vincent, 1977) , as one would expect a minimum of 4 half-lives to elapse before blood counts return to normal by a process of gradual cell loss.
The increased cellularity seen after 1 day following culture of cells from patients treated with rhG-CSF probably reflects the presence of proliferating precursor cells in peripheral blood at the time of sampling, and does not appear to be influenced by the addition of rhG-CSF to the in vitro cultures. Thus, while the initial increase in peripheral neutrophils in vivo almost certainly reflects a release of myeloid cells from the bone marrow, the sustained increase presumably reflects increased proliferative activity in the bone marrow, rather than more prolonged survival of circulating cells.
Indeed, this stimulation of haemopoiesis in vivo in the bone marrow was directly demonstrated by the 20% increase in bone marrow cellularity seen in bone marrow trephines after the infusion of growth factor and by a significant increase in the myeloid-erythroid ratio in bone marrow aspirates. Bone marrow cellularity at the time of recovery from the chemotherapy induced neutrophil nadir (day 15) when rhG-CSF was given after the sixth and last chemotherapy cycle was similar to that observed after the infusion of growth factor during the phase I part of the study. Most of the expansion in cell numbers probably occurs after the GM-CFC stage, as the increase in the proportion of cycling haemopoietic progenitor cells was only small (median of 8.5%). However, we cannot exclude a fractional stimulatory effect of rhG-CSF on GM-CFC cells in patients, as the GM-CFC/BFU-E ratio was often slightly increased after growth factor treatment, although this increase did not reach statistical significance. Of course, the presence of other factors, such as interleukin-l(IL-1), in patients with advanced lung cancer is likely, and the known interactions between IL-1 and rhG-CSF (Moore & Warren, 1987) preclude any simplistic interpretation in the in vivo effects of rhG-CSF.
The median survival of the eight evaluable patients with histologically proven advanced small cell lung cancer in this study is now 8 months and four patients remain alive and on follow up. This survival is consistent with that of currently employed chemotherapy regimes (Aisner, 1987) .
Our results in patients suggest that, when given as a continuous infusion at 1-40ugkg-1day-1, rhG-CSF results in a specific increase in peripheral neutrophils and neutrophil precursors.
